List of Excipients in Branded Drug TEVETEN HCT

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	TEVETEN HCT	eprosartan mesylate and hydrochlorothiazide	54868-5281	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	TEVETEN HCT	eprosartan mesylate and hydrochlorothiazide	54868-5281	CROSPOVIDONE
Physicians Total Care Inc	TEVETEN HCT	eprosartan mesylate and hydrochlorothiazide	54868-5281	FERRIC OXIDE YELLOW
Physicians Total Care Inc	TEVETEN HCT	eprosartan mesylate and hydrochlorothiazide	54868-5281	FERROSOFERRIC OXIDE

Teveten HCT Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Teveten HCT is the fixed-dose combination of eprosartan mesylate and hydrochlorothiazide, marketed in the United States in 600 mg/12.5 mg and 600 mg/25 mg tablets. The product’s commercial value now lies primarily in generic substitution, regional licensing, lifecycle reformulation, and contract manufacturing rather than branded sales. Its excipient system is conventional and does not appear to create a major proprietary barrier, but formulation execution remains important because eprosartan has challenging biopharmaceutical characteristics and the combination must meet bioequivalence requirements for both active ingredients.

What is Teveten HCT and what are its approved strengths?

Teveten HCT combines an angiotensin II receptor blocker with a thiazide diuretic:

Attribute	Teveten HCT
Active ingredients	Eprosartan mesylate and hydrochlorothiazide
Strengths	600 mg/12.5 mg; 600 mg/25 mg
Dosage form	Immediate-release film-coated tablet
Therapeutic class	Antihypertensive combination
Original manufacturer	Solvay Pharmaceuticals; later associated with Abbott/AbbVie commercial operations
Regulatory pathway	New drug application
Primary use	Hypertension
Combination rationale	Renin-angiotensin system blockade plus diuretic-mediated volume reduction

Eprosartan selectively blocks the angiotensin II AT1 receptor. Hydrochlorothiazide increases renal sodium and water excretion. The combination targets patients whose blood pressure is inadequately controlled with either component alone.

The fixed-dose strengths are commercially logical because 12.5 mg is a standard low-dose hydrochlorothiazide increment, while 25 mg provides a higher diuretic dose without changing the eprosartan exposure.

What excipients are used in Teveten HCT?

The U.S. prescribing information identifies conventional tablet and film-coating excipients. Public labeling has identified excipient classes including lactose monohydrate, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, talc, and titanium dioxide. Exact quantities and supplier grades are not disclosed in the public label. [1]

Excipient	Likely functional role	Development relevance
Lactose monohydrate	Diluent and compressibility aid	Creates a lactose-intolerance and reducing-sugar compatibility consideration
Microcrystalline cellulose	Diluent, dry binder, disintegration support	Supports direct compression and tablet robustness
Crospovidone	Superdisintegrant	Helps offset the high drug load and promote rapid tablet breakup
Colloidal silicon dioxide	Glidant and moisture-flow aid	Improves powder flow during high-load compression
Magnesium stearate	Lubricant	Requires control because over-lubrication can slow dissolution
Hypromellose	Film-forming polymer	Provides coating integrity and swallowability
Talc	Anti-tacking and coating aid	Supports film-coating processing
Titanium dioxide	Opacifier and color-control agent	Improves visual uniformity and light protection

The formulation is notable for its high eprosartan drug load. The 600 mg eprosartan component dominates tablet mass, making powder flow, compactability, blend uniformity, and dissolution more important than in many lower-dose antihypertensive combinations.

Why does the excipient system matter?

Eprosartan mesylate is a high-dose active pharmaceutical ingredient. The formulation therefore has less room for large excipient quantities without increasing tablet size. A generic developer must balance:

• tablet weight and patient acceptability;
• hardness and friability;
• disintegration time;
• dissolution of both active ingredients;
• content uniformity;
• lubricant sensitivity;
• coating performance;
• stability under humidity and temperature stress.

Hydrochlorothiazide is present at a much lower dose but remains important for blend uniformity. Segregation risk can arise from the difference between the 600 mg eprosartan load and the 12.5 mg or 25 mg hydrochlorothiazide dose.

What excipient strategy is appropriate for a generic Teveten HCT?

A direct-compression platform is the most commercially attractive starting point if the chosen grades provide adequate flow and compactability. The formulation should preserve the functional roles of the reference product while avoiding unnecessary excipient proliferation.

Recommended development platform

A practical platform would use:

1. A high-functionality diluent system based on microcrystalline cellulose, with lactose retained only if compatibility and regulatory considerations support it.
2. Crospovidone as the principal superdisintegrant.
3. Colloidal silicon dioxide at a controlled level to improve flow without excessive dusting or segregation.
4. Magnesium stearate with a tightly controlled blending time.
5. A conventional hypromellose film coat using titanium dioxide and, where necessary, an approved colorant to distinguish the strengths.

The formulation should be developed against the reference product using comparative dissolution across multiple pH conditions. The key objective is not simply rapid dissolution. It is matching the reference product’s dissolution profile for both eprosartan and hydrochlorothiazide.

Should a developer use lactose?

Lactose is commercially efficient and common in oral solid dosage forms. It supports acceptable tablet compaction and can reduce development cost. A lactose-free formulation may still offer value where:

• the target market has a strong preference for lactose-free products;
• the developer wants to avoid reducing-sugar compatibility concerns;
• the formulation uses a high-functionality cellulose or mannitol platform;
• a differentiated excipient claim is commercially meaningful.

Removing lactose does not automatically create meaningful market exclusivity. It can support product positioning, but a generic product must still demonstrate pharmaceutical equivalence and bioequivalence under the applicable regulatory pathway.

Is mannitol a viable replacement?

Mannitol can improve mouthfeel and provide a non-lactose diluent option, but it is generally more expensive and may require a different compression strategy. It can also affect tablet hardness, dissolution, and moisture behavior. Its commercial value is greater in a chewable, orally disintegrating, or patient-preference product than in a conventional swallowed tablet.

Is wet granulation justified?

Wet granulation may improve content uniformity and reduce segregation, particularly for hydrochlorothiazide. It also adds process complexity, water exposure, drying requirements, and cost. A wet-granulated product may be appropriate if direct compression cannot control blend uniformity or tablet mechanical properties.

For a low-margin antihypertensive generic, wet granulation is commercially attractive only when it solves a defined quality problem. Otherwise, it can erode the product’s cost advantage.

What formulation patents protect Teveten HCT?

The primary commercial barriers for Teveten HCT were associated with the original drug product, active ingredients, combination claims, and regulatory exclusivity. Publicly available information does not establish a currently enforceable, commercially material U.S. formulation-patent barrier covering the original Teveten HCT product.

The relevant distinction is between:

• patents covering eprosartan or eprosartan salts;
• patents covering hydrochlorothiazide;
• combination or treatment patents;
• formulation and stability patents;
• process patents;
• patents listed in the FDA Orange Book.

A formulation patent matters to generic entry only if it is unexpired, enforceable, relevant to the proposed product, and listed or otherwise capable of supporting an infringement action. An expired or delisted patent does not create a current U.S. launch barrier.

The FDA Orange Book should be reviewed for the product’s current listing status and any patents historically associated with the NDA. [2] Patent status should also be checked in the USPTO Patent Center and commercial patent databases before filing or licensing decisions.

When does Teveten HCT lose exclusivity?

Teveten HCT’s core U.S. exclusivity period has expired. The product is not a current high-value U.S. brand with meaningful new-chemical-entity exclusivity. The principal commercial question is therefore not loss of branded exclusivity but whether a generic can obtain approval and achieve sufficient volume.

Exclusivity category	Teveten HCT position
New chemical entity exclusivity	Expired
Standard NDA exclusivity	Expired
Pediatric exclusivity	No current commercial barrier identified
Orphan exclusivity	Not applicable
Core composition protection	Expired or no longer commercially controlling
Current U.S. branded exclusivity	No meaningful current protection identified

The FDA’s Orange Book identifies approved drug products and relevant patent or exclusivity information. A product may remain listed as discontinued even when generic development remains legally possible. Discontinuation does not by itself establish withdrawal for safety or effectiveness. [2]

What is the FDA regulatory status of Teveten HCT?

Teveten HCT was approved in the United States as an oral antihypertensive combination. The reference product is no longer a major active branded product in the U.S. market. FDA labeling and historical regulatory records remain relevant for identifying the reference strengths, dosage form, indications, contraindications, warnings, and inactive ingredients. [1]

A prospective generic applicant would normally evaluate an abbreviated new drug application, provided the reference product and regulatory pathway remain suitable. The applicant would need to address:

• pharmaceutical equivalence;
• bioequivalence for eprosartan and hydrochlorothiazide;
• comparative dissolution;
• strength-specific formulation performance;
• impurity and degradation-product controls;
• stability;
• labeling conformity;
• manufacturing-site qualification.

A 505(b)(2) strategy could become relevant for a materially different dosage form, delivery system, or dosing regimen. It would be less efficient for a conventional immediate-release tablet that can be developed as an ANDA.

Are Paragraph IV challenges relevant to Teveten HCT?

A Paragraph IV certification is relevant only where an ANDA applicant identifies an unexpired patent listed for the reference product and asserts that the patent is invalid, unenforceable, or not infringed. Because the principal exclusivity period for Teveten HCT has expired, a new Paragraph IV strategy is unlikely to be the central commercial issue unless an unexpired, listed patent is identified.

The practical sequence is:

1. Confirm the current Orange Book listing.
2. Identify any unexpired patents associated with the NDA.
3. Determine whether the proposed product practices the claims.
4. Select Paragraph III, Paragraph IV, or a certification based on patent status.
5. Assess whether a 30-month stay could be triggered by patent-holder litigation.

A filing based solely on the assumption that all historical patents have expired would create avoidable litigation risk. Historical patent records and current Orange Book data must be reconciled before ANDA submission.

What generic entry risks exist for Teveten HCT?

The largest risks are commercial and technical rather than exclusivity-driven.

Technical risks

The main technical risks are:

• inadequate blend uniformity for low-dose hydrochlorothiazide;
• slow or variable eprosartan dissolution;
• excessive tablet size;
• sensitivity to lubricant concentration;
• manufacturing variability caused by high drug loading;
• dissolution differences caused by excipient grade changes;
• stability issues involving moisture, coating, or API polymorphism.

Regulatory risks

Regulatory risks include:

• failure to match the reference product’s dosage form and release characteristics;
• inadequate justification for inactive-ingredient differences;
• insufficient comparative dissolution data;
• weak control of impurities or degradation products;
• inability to source reference-comparable API;
• discontinuation or unavailability of a suitable reference product.

Commercial risks

The commercial risks are more significant:

• low prescription volume;
• competition from inexpensive ARB/thiazide combinations;
• physician preference for losartan/hydrochlorothiazide, valsartan/hydrochlorothiazide, or irbesartan/hydrochlorothiazide;
• limited formulary incentives;
• wholesaler reluctance to add a low-volume SKU;
• price erosion after multiple generic entrants;
• absence of a strong brand franchise.

How does Teveten HCT compare with competing ARB/thiazide products?

Teveten HCT competes in a crowded fixed-dose combination market.

Product	ARB	Thiazide	Commercial position
Teveten HCT	Eprosartan	Hydrochlorothiazide	Niche and largely legacy product
Hyzaar	Losartan	Hydrochlorothiazide	Broad generic availability and strong historical recognition
Diovan HCT	Valsartan	Hydrochlorothiazide	Established ARB combination with broad clinical familiarity
Avalide	Irbesartan	Hydrochlorothiazide	Established generic combination
Benicar HCT	Olmesartan	Hydrochlorothiazide	Stronger branded and specialty-market history
Micardis HCT	Telmisartan	Hydrochlorothiazide	Differentiated by telmisartan’s long half-life and market positioning

Teveten HCT lacks the current brand strength and market scale of the leading ARB/thiazide combinations. A generic manufacturer would need a low-cost operating model or a targeted regional strategy.

What commercial opportunities exist for Teveten HCT?

Generic fixed-dose combination

The clearest opportunity is a conventional generic tablet in both 600 mg/12.5 mg and 600 mg/25 mg strengths. The opportunity is strongest in markets where:

• eprosartan remains included in treatment guidelines or reimbursement formularies;
• local generic competition is limited;
• the reference product has remained registered;
• the manufacturer can use an existing ARB-combination manufacturing platform.

Regional licensing

Eprosartan has had different commercial histories across jurisdictions. A regional license can be more attractive than a U.S.-only launch where the product has low demand. Potential targets include markets with:

• continued eprosartan prescribing;
• national tender systems;
• limited local competition;
• established antihypertensive generic procurement;
• accessible regulatory pathways for line extensions.

The license should cover product registration, API supply, trademark rights, pharmacovigilance, and the right to introduce lactose-free or strength-differentiated variants.

Excipient-differentiated reformulation

A lactose-free tablet, low-dust formulation, or smaller tablet could create a modest commercial distinction. The differentiation would not support premium pricing in most generic markets unless linked to a clear procurement or patient-adherence benefit.

Contract manufacturing

Manufacturers with existing high-dose immediate-release tablet capacity can add Teveten HCT to an established platform. The product may be useful as a portfolio filler where the same equipment already handles:

• ARBs;
• hydrochlorothiazide products;
• high-load direct-compression tablets;
• conventional hypromellose film coatings.

Combination-product portfolio expansion

A company with eprosartan monotherapy or other antihypertensive products could use Teveten HCT as a portfolio extension. The value would come from channel access, tender participation, and prescriber continuity rather than product-level innovation.

Is there biosimilar risk for Teveten HCT?

No. Teveten HCT is a chemically synthesized small-molecule combination, not a biologic. Biosimilar regulation does not apply. The relevant competitors are small-molecule generics, authorized generics, branded combination products, and therapeutic substitutes.

What manufacturing and intellectual-property barriers remain?

The manufacturing barrier is moderate. The product does not require sterile production, biologic processing, complex delivery technology, or specialized device engineering. The main manufacturing challenge is the combination of high eprosartan loading with low-dose hydrochlorothiazide uniformity.

Potential IP barriers may arise from:

• API salt or polymorph claims;
• process patents;
• crystalline-form claims;
• impurity-control methods;
• formulation patents;
• jurisdiction-specific combination or method-of-use claims.

These risks must be assessed separately by country. U.S. patent expiry does not establish freedom to operate in Europe, Japan, Canada, Latin America, or emerging markets.

What is the likely revenue exposure?

Teveten HCT should be treated as a low-to-moderate revenue opportunity unless a specific market has persistent eprosartan demand and limited competition. Revenue potential depends on:

• market size for eprosartan-containing products;
• number of approved generic suppliers;
• reimbursement status;
• tender concentration;
• API cost;
• minimum efficient batch size;
• distribution fees;
• ability to sell both strengths.

The 600 mg/12.5 mg strength is likely to have broader use because low-dose hydrochlorothiazide is a standard starting combination. The 600 mg/25 mg strength may generate lower volume but is important for formulary completeness and physician substitution.

Key Takeaways

• Teveten HCT contains eprosartan mesylate and hydrochlorothiazide in 600 mg/12.5 mg and 600 mg/25 mg immediate-release tablets.
• Its public excipient system is conventional: lactose, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, hypromellose, talc, and titanium dioxide.
• The formulation’s main technical challenge is high-dose eprosartan combined with low-dose hydrochlorothiazide.
• Direct compression is the preferred initial development approach if blend uniformity and dissolution can be controlled.
• A lactose-free formulation may offer limited differentiation but is unlikely to create durable exclusivity.
• Core U.S. exclusivity has expired, and no current branded patent barrier is identified from the available public product information.
• Paragraph IV risk is secondary unless an unexpired Orange Book-listed patent is confirmed.
• The strongest opportunities are generic supply, regional licensing, contract manufacturing, and portfolio expansion.
• Biosimilar risk is irrelevant because Teveten HCT is a small-molecule product.
• Commercial upside is constrained by competition from losartan, valsartan, irbesartan, olmesartan, and telmisartan hydrochlorothiazide combinations.

FAQs

Can Teveten HCT be reformulated without lactose?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or another suitable diluent. The replacement must preserve content uniformity, tablet strength, disintegration, dissolution, and stability.

Is eprosartan hydrochlorothiazide a difficult generic combination?

It is moderately challenging. The high eprosartan dose increases tablet-size and compression constraints, while the low hydrochlorothiazide dose creates blend-uniformity risk.

Does Teveten HCT require a special drug-delivery technology?

No. The reference product is an immediate-release film-coated tablet. A modified-release or device-based system would require a different regulatory and commercial justification.

Which Teveten HCT strength is more commercially attractive?

The 600 mg/12.5 mg strength is generally the more attractive lead product because low-dose hydrochlorothiazide is widely used in fixed-dose antihypertensive therapy. Both strengths may be needed for regulatory and commercial completeness.

Can a manufacturer obtain premium pricing for a Teveten HCT lactose-free version?

Usually not in a conventional generic market. Premium pricing would require a strong payer, procurement, adherence, or patient-preference rationale that exceeds the cost of the formulation change.

References

1. U.S. Food and Drug Administration. (n.d.). Teveten HCT prescribing information: Eprosartan mesylate and hydrochlorothiazide tablets. FDA-approved labeling.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.

3. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. FDA.

4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process and generic drug requirements. FDA.